|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
CAP '14 Annual Meeting: Sept. 7-10, Chicago, Illinois
FSP 2015 Annual Anatomic Pathology Conference: Feb. 13-15, 2015
The FSP Summer Anatomic Pathology Conference held July 13 and 14, 2014 was a tremendous success. We heard sensational talks from Geza Acs, M.D., PhD, Teri A. Longacre, M.D. and Bruce Smoller, M.D. Thank you for sharing your knowledge with us! The attendees enjoyed the science and the social networking as well as the learning in the Exhibit Hall with our partners. A special thanks to our Platinum Sponsor: NeoGenomics Laboratories and Vitro Molecular Laboratories who contributed as well! Thank you! Thanks also go to our vendors.
Study: 5 percent of patients in outpatient settings misdiagnosed, offering pathologists opportunity to provide more consultations to doctors
Publication of new peer-reviewed clinical studies indicates that, within the United States, more than 5 percent of outpatients, or 12 million people, are misdiagnosed annually. Few pathologists and clinical laboratory scientists would dispute this number because every day they see the best and the worst of how physicians use medical laboratory tests.
Study shows 3rd gene as indicator for breast cancer
The New York Times
Mutations in a gene called PALB2 raise the risk of breast cancer in women by almost as much as mutations in BRCA1 and BRCA2, the infamous genes implicated in most inherited cases of the disease, a team of researchers reported. Previous data had indicated that mutations in PALB2 were linked to breast cancer, and many genetic tests already screen for them. But it had not been clear to what extent these mutations raised a carrier's odds of developing the disease.
A junior doctor's salary
Doctors are spending more and more time in residency and fellowship programs — sometimes up to a decade — but their salaries during those years (accounting for inflation) haven't increased in 40 years. Factoring in time spent in school and residency, one study from economists at Yale recently found that the average female primary care physician would have made more money over the course of her career had she been a physician assistant.
Practice management, revenue cycle vendors form industry group
Practice management systems vendors, including those who provide revenue cycle management and patient scheduling applications, will now have a new, unified voice within the healthcare industry. The Healthcare Administrative Technology Association, a nonprofit trade association, is now asking PMS vendors to join in discussions and advocacy programs centered around their critical role in the healthcare ecosystem.
Empathy in clinical healthcare
The Huffington Post
Patients seek out physicians not only for diagnosis and treatment of "organic" pain, but for pain which results from suffering in this day-to-day world, pain which transcends the body and derives from the psyche. This pain cannot be diagnosed or treated through pharmaceutical or technological means. The physician's task is to determine an appropriate diagnosis, workup and treatment for all types of pain — but this does not involve simply testing, scanning and medication. The diagnosis needs science for cure, but the illness needs the physician to adequately address the pain of the entire person.
Following state permit, New York Genome Center's clinical lab prepares to submit exome, genome tests
The New York Genome Center's new clinical laboratory has obtained a permit from the New York State Department of Health and is preparing to submit its first clinical sequencing test — an exome test for inherited disorders — to the state, Clinical Sequencing News has learned. By the end of this year, the lab plans to also submit a whole-genome test for inherited, or constitutional, disorders and a whole-genome and transcriptome test for cancer.
Biomarker panel developed for early detection of esophageal cancer
Oncology Nurse Advisor
A research team has developed and validated a four-protein serum biomarker panel that holds significant promise for early detection of esophageal cancer, a relatively rare but often deadly disease that has grown in incidence over the past several decades. The four-protein panel, called B-AMP (biglycan, myeloperoxidase, annexin-A6, and protein S100-A9), is a simple, noninvasive, low-cost blood test.
Where will Cologuard fit into CRC screening?
Recently, a stool DNA test (Cologuard, Exact Sciences) was approved for colorectal cancer, or CRC, screening by the US Food and Drug Administration, but where will the new test fit in?The noninvasive test joins a litany of options that clinicians can now offer individuals eligible for screening. Although the screening "gold standard" in the United States is colonoscopy, many adults avoid the invasive procedure. Until now, the most commonly used noninvasive alternatives have been based solely on analyses of blood in the stool. Cologuard is also based on stool DNA, and has been shown to be significantly more sensitive.
Disclaimer: The authors, editors, and the Florida Society of Pathologists (FSP) Executive Committee affiliated with "Florida Pathology Today" e-Newsletter cannot and do not warrant the completeness, accuracy, non-infringement, merchantability, timeliness or fitness for a particular purpose of the information or views contained within this publication, or available through the links provided within articles contained within this publication.
FSP has no control over and does not officially endorse the content of the information available on the links contained in the "Florida Pathology Today" or links imbedded in articles within the "Florida Pathology Today." These links are provided as a courtesy only. Linked sites are not a part of the "Florida Pathology Today." The owners of those linked sites, and not FSP, own the intellectual property rights to the material on the linked sites. FSP cannot certify the accuracy of material published on linked sites. Additionally, the contents of this e-Newsletter and the above referenced links, including any advice, suggestions, and/or recommendations have NOT been generated as part of any professional evaluation.
The authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" e-Newsletter shall not be liable to anyone for any loss or injury caused in whole or in part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting or delivering this e-Newsletter and any information included in this e-Newsletter.
Under no circumstances will the authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" be liable to you or anyone else for any decision made or any action taken by you or anyone else in reliance on such information or view, or for any incidental, consequential, special, or similar damages even if advised of the possibility of such damages.
The above warranties are the only warranties of any kind either expressed or implied, including warranties of merchantability or fitness for any particular purpose.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063